Habibollah Arefian

Dr. Habibollah Arefian

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Journal of Infection
Verified
Journal Article
Closed access
HAHabibollah Arefian
Habibollah Arefian
SHSteffen Heublein
Steffen Heublein
ASAndré Scherag
André Scherag
FBFrank Martin Brunkhorst
Frank Martin Brunkhorst
MYMustafa Z. Younis
Mustafa Z. Younis
MHMichael Hartmann
Michael Hartmann

1 February 2016 in American Journal of Infection Control
Verified
Journal Article
Closed access
HAHabibollah Arefian
Habibollah Arefian
SHStefan Hagel
Stefan Hagel
SHSteffen Heublein
Steffen Heublein
FRFlorian Rissner
Florian Rissner
ASAndré Scherag
André Scherag
MHMichael Hartmann
Michael Hartmann

5 January 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HAHabibollah Arefian
Habibollah Arefian
MVMonique Vogel
Monique Vogel
AKAnja Kwetkat
Anja Kwetkat
MHMichael Hartmann
Michael Hartmann
This systematic review sought to assess the costs and benefits of interventions preventing hospital-acquired infections and to evaluate methodological and reporting quality. We systematically searched Medline via PubMed and the National Health Service Economic Evaluation Database from 2009 to 2014. We included quasi-experimental and randomized trails published in English or German evaluating the economic impact of interventions preventing the four most frequent hospital-acquired infections (urinary tract infections, surgical wound infections, pneumonia, and primary bloodstream infections). Characteristics and results of the included articles were extracted using a standardized data collection form. Study and reporting quality were evaluated using SIGN and CHEERS checklists. All costs were adjusted to 2013 US$. Savings-to-cost ratios and difference values with interquartile ranges (IQRs) per month were calculated, and the effects of study characteristics on the cost-benefit results were analyzed. Our search returned 2067 articles, of which 27 met the inclusion criteria. The median savings-to-cost ratio across all studies reporting both costs and savings values was US $7.0 (IQR 4.2–30.9), and the median net global saving was US $13,179 (IQR 5,106–65,850) per month. The studies’ reporting quality was low. Only 14 articles reported more than half of CHEERS items appropriately. Similarly, an assessment of methodological quality found that only four studies (14.8%) were considered high quality. Prevention programs for hospital acquired infections have very positive cost-benefit ratios. Improved reporting quality in health economics publications is required.

6 August 2018 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
AFAxel Findeisen
Axel Findeisen
HAHabibollah Arefian
Habibollah Arefian
TDTorsten Doenst
Torsten Doenst
SHStefan Hagel
Stefan Hagel
MPMathias W Pletz
Mathias W Pletz
JMJens Maschmann
Jens Maschmann
This study aimed to determine the additional costs and length of stay (LOS) due to surgical site infections (SSIs) after coronary artery bypass grafting (CABG) at Jena University Hospital. The data of 999 consecutive patients who underwent CABG from January 2013 to December 2014 were collected. We extracted the number, type and duration of antimicrobial therapy and V.A.C.® therapy (negative pressure wound therapy) treatments and calculated the additional SSI-related costs based on the hospital's perspective. We also evaluated the prolongation of LOS using a multistate model and calculated the costs due to the additional LOS. In total, 983 patients were included in our analysis, and 126 patients with SSIs following CABG were identified during the study period; 124 patients with SSIs (98.4%) were discharged alive. The mean cost of antimicrobial therapy to treat the SSIs was €818 [95% confidence interval (CI) 392-1245], and the mean cost of V.A.C. therapy was €1179 (95% CI 748-1610) per infected patient. The mean additional LOS due to SSIs (±standard error) was estimated to be 9.3 ± 2.6 days. The cost per SSI-infected patient attributable to the additional LOS was €9444 (95% CI 4242-14 645). SSIs following CABG are associated with an additional LOS and a significant economic burden depending on the classification of SSI. A very important component of the additional cost is the prolongation of LOS. Therefore, it is essential to shorten the hospital stay due to SSIs as far as possible.

17 May 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HAHabibollah Arefian
Habibollah Arefian
SHStefan Hagel
Stefan Hagel
DFDagmar Fischer
Dagmar Fischer
ASAndré Scherag
André Scherag
FBFrank Martin Brunkhorst
Frank Martin Brunkhorst
MHMichael Hartmann
Michael Hartmann
Healthcare-associated infections (HAIs) are a major health concern and have substantial effects on morbidity and mortality and increase healthcare costs. We investigated the effect of a hospital-wide program for the prevention of HAIs on additional length of stay (LOS). We analyzed data from a prospective, single-center, quasi-experimental study with two surveillance periods before and after implementation of an infection prevention intervention program. HAI diagnosis was made according to surveillance definition criteria established by the US Centers for Disease Control and Prevention. A multistate model was used to estimate additional LOS for patients with HAI in both surveillance periods. During the first and second periods, 1,568 and 2,336 HAIs were identified among 26,943 and 35,211 patients, respectively. For HAI patients exclusively treated in a general ward, additional LOS was 8.4 (95% confidence interval, CI: 6.8–10.0) days in the first period and 9.6 (95% CI: 8.3–11.0) days in the second period (p = 0.26). For HAI patients treated in both an intensive care unit (ICU) and a general ward, additional LOS was 8.1 (95% CI: 6.3–9.9) days in the first period to 7.3 (95% CI: 6.1–8.5) days in the second period (p = 0.47). Healthcare-associated infections prolong LOS. A hospital-wide infection control program did not alter the prolongation of LOS.

21 April 2020 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
MSMaximilian Sieg
Maximilian Sieg
MHMichael Hartmann
Michael Hartmann
USUtz Settmacher
Utz Settmacher
HAHabibollah Arefian
Habibollah Arefian
Cabozantinib was approved by the European Medicines Agency and the Federal Drug Administration as an option for sorafenib-resistant advanced hepatocellular carcinoma, increasing overall survival and progression-free survival compared with placebo. We evaluated the cost-effectiveness of cabozantinib in the second-line setting for patients with an advanced hepatocellular carcinoma from the German statutory health insurance perspective compared with an US scenario using US prices. A Markov model was developed to compare the costs and effectiveness of cabozantinib with best supportive care in the second-line treatment of advanced hepatocellular carcinoma over a lifetime horizon. Health outcomes were measured in discounted life years and discounted quality-adjusted life years. Survival probabilities were estimated using parametric survival distributions based on CELESTIAL trial data. Utilities were derived from the literature. Costs contained drugs, monitoring and adverse events measured in US Dollars. Model robustness was addressed in univariable, scenario and probabilistic sensitivity analyses. Cabozantinib generated a gain of 0.18 life years (0.15 quality-adjusted life years) compared with best supportive care. The total mean cost per patient was $56,621 for cabozantinib and $2064 for best supportive care in the German model resulting in incremental cost-effectiveness ratios for cabozantinib of $306,778/life year and $375,470/quality-adjusted life year. Using US prices generated costs of $177,496 for cabozantinib and $4630 for best supportive care and incremental cost-effectiveness ratios of $972,049/life year and $1,189,706/quality-adjusted life year. Our analysis established that assuming a willingness-to-pay threshold of $163,371/life year (quality-adjusted life year) for the German model and $188,559/life year (quality-adjusted life year) for the US model, cabozantinib is not cost-effective compared with best supportive care. Sensitivity analyses showed that cabozantinib was not cost-effective in almost all our scenarios.